Ovarian Cancer Prevention

  • Kathryn Coe
  • Ana Maria Lopez
  • Lisa M. Hess


Ovarian Cancer Epithelial Ovarian Cancer Estrogen Replacement Therapy Ovarian Surface Epithelium Ovarian Cancer Risk 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Averette, H.E., M.F. Janicek, et al. (1995). "The National Cancer Data Base report on ovarian cancer. American College of Surgeons Commission on Cancer and the American Cancer Society." Cancer 76(6): 1096–1103.PubMedGoogle Scholar
  2. Bai, W., B. Oliveros-Saunders, et al. (2000). "Estrogen stimulation of ovarian surface epithelial cell proliferation." In Vitro Cell Dev Biol Anim 36(10): 657–666.CrossRefPubMedGoogle Scholar
  3. Barda, G., J. Menczer, et al. (2004). "Comparison between primary peritoneal and epithelial ovarian carcinoma: a population-based study." Am J Obstet Gynecol 190(4): 1039–1045.CrossRefPubMedGoogle Scholar
  4. Bray, F., A. H. Loos, et al. (2005). "Ovarian cancer in Europe: Cross-sectional trends in incidence and mortality in 28 countries, 1953–2000." Int J Cancer 113(6): 977–990.CrossRefPubMedGoogle Scholar
  5. Brewster, D. H., C.S. Thomson, et al. (2001). "Relation between socioeconomic status and tumour stage in patients with breast, colorectal, ovarian, and lung cancer: results from four national, population based studies." BMJ 322(7290): 830–831.CrossRefPubMedGoogle Scholar
  6. Buamah, P. (2000). "Benign conditions associated with raised serum CA-125 concentration." J Surg Oncol 75(4): 264–265.CrossRefPubMedGoogle Scholar
  7. Canman, C. E., C.Y. Chen, et al. (1994). "DNA damage responses: p53 induction, cell cycle perturbations, and apoptosis." Cold Spring Harb Symp Quant Biol 59: 277–286.PubMedGoogle Scholar
  8. Claus, E.B., J.M. Schildkraut, et al. (1996). "The genetic attributable risk of breast and ovarian cancer." Cancer 77(11): 2318–2324.CrossRefPubMedGoogle Scholar
  9. Cottreau, C.M., R.B. Ness, et al. (2000). "Physical activity and reduced risk of ovarian cancer." Obstet Gynecol 96(4): 609–614.CrossRefPubMedGoogle Scholar
  10. Couzin, J. (2003). "Choices — and uncertainties — for women with BRCA mutations." Science 302(5645): 592.CrossRefPubMedGoogle Scholar
  11. Cramer, D.W., E.R. Greenberg, et al. (2000). "A case-control study of galactose consumption and metabolism in relation to ovarian cancer." Cancer Epidemiol Biomarkers Prev 9(1): 95–101.PubMedGoogle Scholar
  12. Cramer, D.W., B.L. Harlow, et al. (1998). "Over-the-counter analgesics and risk of ovarian cancer." Lancet 351(9096): 104–107.CrossRefPubMedGoogle Scholar
  13. Cramer, D.W. and H. Xu (1995). "Epidemiologic evidence for uterine growth factors in the pathogenesis of ovarian cancer." Ann Epidemiol 5(4): 310–314.CrossRefPubMedGoogle Scholar
  14. Daly, M. and G.I. Obrams (1998). "Epidemiology and risk assessment for ovarian cancer." Semin Oncol 25(3): 255–264.PubMedGoogle Scholar
  15. Daly, M. B. (1992). "The epidemiology of ovarian cancer." Hematol Oncol Clin North Am 6(4): 729–738.Google Scholar
  16. De Palo, G., U. Veronesi, et al. (1995). "Can fenretinide protect women against ovarian cancer?" J Natl Cancer Inst 87(2): 146–147.PubMedGoogle Scholar
  17. De Rosa, V., M.L. Mangoni di Stefano, et al. (1995). "Computed tomography and second-look surgery in ovarian cancer patients. Correlation, actual role and limitations of CT scan." Eur J Gynaecol Oncol 16(2): 123–129.PubMedGoogle Scholar
  18. Delia, D., A. Aiello, et al. (1993). "N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid." Cancer Res 53(24): 6036–6041.PubMedGoogle Scholar
  19. DHHS (1996). "Ovarian Cancer: Screening, Treatment and Followup." NIH Consensus Statement 12(3): April 5–7.Google Scholar
  20. Drake, J.G. and J.L. Becker (2002). "Aspirin-induced inhibition of ovarian tumor cell growth." Obstet Gynecol 100(4): 677–682.CrossRefPubMedGoogle Scholar
  21. Drew, S.V. (2001). "Oestrogen replacement therapy and ovarian cancer." Lancet 358(9296): 1910.CrossRefGoogle Scholar
  22. Edmondson, R.J. and J.M. Monaghan (2001). "The epidemiology of ovarian cancer." Int J Gynecol Cancer 11(6): 423–429.CrossRefPubMedGoogle Scholar
  23. el-Bayoumy, K., P. Upadhyaya, et al. (1995). "Chemoprevention of cancer by organoselenium compounds." J Cell Biochem Suppl 22: 92–100.CrossRefPubMedGoogle Scholar
  24. Fairfield, K.M., D.J. Hunter, et al. (2002). "Aspirin, other NSAIDs, and ovarian cancer risk (United States)." Cancer Causes Control 13(6): 535–542.CrossRefPubMedGoogle Scholar
  25. Fairfield, K.M., W.C. Willett, et al. (2002). "Obesity, weight gain, and ovarian cancer." Obstet Gynecol 100(2): 288–296.CrossRefPubMedGoogle Scholar
  26. Ferrandina, G., F.O. Ranelletti, et al. (2002). "Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer." Gynecol Oncol 85(2): 305–310.CrossRefPubMedGoogle Scholar
  27. Flegal, K. M., M. D. Carroll, et al. (2002). "Prevalence and trends in obesity among US adults, 1999–2000." JAMA 288(14): 1723–1727.CrossRefPubMedGoogle Scholar
  28. Formelli, F. and L. Cleris (1993). "Synthetic retinoid fenretinide is effective against a human ovarian carcinoma xenograft and potentiates cisplatin activity." Cancer Res 53(22): 5374–5376.PubMedGoogle Scholar
  29. Gladstone, C.Q. (1994). Screening for ovarian cancer. In: Canadian Task Force on the Periodic Health Examination. Canadian Guide to Clinical Preventive Health Care. Ottawa, Health Canada: 870–881.Google Scholar
  30. Gloeckler Ries, L.A., M.E. Reichman, et al. (2003). "Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program." Oncologist 8(6): 541–552.CrossRefPubMedGoogle Scholar
  31. Goff, B.A., L.S. Mandel, et al. (2004). "Frequency of symptoms of ovarian cancer in women presenting to primary care clinics." JAMA 291(22): 2705–2712.CrossRefPubMedGoogle Scholar
  32. Goodman, M.T., C.N. Correa, et al. (2003). "Stage at diagnosis of ovarian cancer in the United States, 1992–1997." Cancer 97(10 Suppl): 2648–2659.CrossRefPubMedGoogle Scholar
  33. Hakama, M., U.H. Stenman, et al. (1996). "CA 125 as a screening test for ovarian cancer." J Med Screen 3(1): 40–42.PubMedGoogle Scholar
  34. Hankinson, S.E., G.A. Colditz, et al. (1995). "A prospective study of reproductive factors and risk of epithelial ovarian cancer." Cancer 76(2): 284–290.PubMedGoogle Scholar
  35. Hildreth, N.G., J.L. Kelsey, et al. (1981). "An epidemiologic study of epithelial carcinoma of the ovary." Am J Epidemiol 114(3): 398–405.PubMedGoogle Scholar
  36. Holschneider, C.H. and J.S. Berek (2000). "Ovarian cancer: epidemiology, biology, and prognostic factors." Semin Surg Oncol 19(1): 3–10.CrossRefPubMedGoogle Scholar
  37. Huncharek, M. and B. Kupelnick (2001). "Dietary fat intake and risk of epithelial ovarian cancer: a meta-analysis of 6,689 subjects from 8 observational studies." Nutr Cancer 40(2): 87–91.CrossRefPubMedGoogle Scholar
  38. Jacobs, I. (1998). Overview-progress in screening for ovarian cancer. In: Ovarian Cancer. F. Sharp, A. Blackett, et al. (Eds.). Oxford, Isis Medical Media.Google Scholar
  39. Jemal, A., R.C. Tiwari, et al. (2004). "Cancer statistics, 2004." CA Cancer J Clin 54(1): 8–29.PubMedGoogle Scholar
  40. John, E.M., A.S. Whittemore, et al. (1993). "Characteristics relating to ovarian cancer risk: collaborative analysis of seven U.S. case-control studies. Epithelial ovarian cancer in black women. Collaborative Ovarian Cancer Group." J Natl Cancer Inst 85(2): 142–147.PubMedGoogle Scholar
  41. Katchy, K.C. and N.D. Briggs (1992). "Clinical and pathological features of ovarian tumours in Rivers state of Nigeria." East Afr Med J 69(8): 456–459.PubMedGoogle Scholar
  42. Koifman, S. and R. Jorge Koifman (2001). "Breast cancer mortality among Ashkenazi Jewish women in Sao Paulo and Porto Alegre, Brazil." Breast Cancer Res 3(4): 270–275.CrossRefPubMedGoogle Scholar
  43. Kumle, M., E. Alsaker, et al. (2003). "[Use of oral contraceptives and risk of cancer, a cohort study]." Tidsskr Nor Laegeforen 123(12): 1653–1656.PubMedGoogle Scholar
  44. Lacey, J.V., Jr., P.J. Mink, et al. (2002). "Menopausal hormone replacement therapy and risk of ovarian cancer." JAMA 288(3): 334–341.CrossRefPubMedGoogle Scholar
  45. Leeper, K., R. Garcia, et al. (2002). "Pathologic findings in prophylactic oophorectomy specimens in high-risk women." Gynecol Oncol 87(1): 52–56.CrossRefPubMedGoogle Scholar
  46. Lipsett, M.B. (1979). "Interaction of drugs, hormones, and nutrition in the causes of cancer." Cancer 43(5 Suppl): 1967–1981.PubMedGoogle Scholar
  47. Malik, I.A. (2002). "A prospective study of clinico-pathological features of epithelial ovarian cancer in Pakistan." J Pak Med Assoc 52(4): 155–158.PubMedGoogle Scholar
  48. Mansfield, C.M. (1993). "A review of the etiology of breast cancer." J Natl Med Assoc 85(3): 217–221.PubMedGoogle Scholar
  49. McGuire, V., L. Herrinton, et al. (2002). "Race, epithelial ovarian cancer survival, and membership in a large health maintenance organization." Epidemiology 13(2): 231–234.CrossRefPubMedGoogle Scholar
  50. Morice, P., P. Pautier, et al. (1999). "Laparoscopic prophylactic oophorectomy in women with inherited risk of ovarian cancer." Eur J Gynaecol Oncol 20(3): 202–204.PubMedGoogle Scholar
  51. Murdoch, W.J. and A.C. McDonnel (2002). "Roles of the ovarian surface epithelium in ovula-tion and carcinogenesis." Reproduction 123(6): 743–750.CrossRefPubMedGoogle Scholar
  52. Narod, S.A., H. Risch, et al. (1998). "Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group." N Engl J Med 339(7): 424–428.CrossRefPubMedGoogle Scholar
  53. Negri, E., S. Franceschi, et al. (1991). "Pooled analysis of 3 European case-control studies: I. Reproductive factors and risk of epithelial ovarian cancer." Int J Cancer 49(1): 50–56.PubMedGoogle Scholar
  54. Ness, R.B., D.W. Cramer, et al. (2002). "Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies." Am J Epidemiol 155(3): 217–224.CrossRefPubMedGoogle Scholar
  55. Ness, R.B., J.A. Grisso, et al. (2000). "Risk of ovarian cancer in relation to estrogen and pro-gestin dose and use characteristics of oral contraceptives. SHARE Study Group. Steroid Hormones and Reproductions." Am J Epidemiol 152(3): 233–241.CrossRefPubMedGoogle Scholar
  56. Nguyen, H.N., H.E. Averette, et al. (1994). "Ovarian carcinoma. A review of the significance of familial risk factors and the role of prophylactic oophorectomy in cancer prevention." Cancer 74(2): 545–555.PubMedGoogle Scholar
  57. Piver, M.S., M.F. Jishi, et al. (1993). "Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry." Cancer 71(9): 2751–2755.PubMedGoogle Scholar
  58. Polednak, A.P. (1992). "Cancer incidence in the Puerto Rican-born population of Connecticut." Cancer 70(5): 1172–1176.PubMedGoogle Scholar
  59. Ponzoni, M., P. Bocca, et al. (1995). "Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation." Cancer Res 55(4): 853–861.PubMedGoogle Scholar
  60. Rebbeck, T.R. (2000). "Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers." JClin Oncol 18(21 Suppl): 100S–103S.Google Scholar
  61. Rebbeck, T.R., A.M. Levin, et al. (1999). "Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers." J Natl Cancer Inst 91(17): 1475–1479.CrossRefPubMedGoogle Scholar
  62. Ries, L.A.G., M.P. Eisner, et al. (2004). SEER Cancer Statistics Review, 1995–2001. Bethesda, MD, National Cancer Institute.Google Scholar
  63. Riman, T., P.W. Dickman, et al. (2002). "Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study." Am J Epidemiol 156(4): 363–373.CrossRefPubMedGoogle Scholar
  64. Risch, H.A., L.D. Marrett, et al. (1994). "Parity, contraception, infertility, and the risk of epithelial ovarian cancer." Am J Epidemiol 140(7): 585–597.PubMedGoogle Scholar
  65. Rodriguez, C, A.V. Patel, et al. (2001). "Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women." Jama 285(11): 1460–1465.CrossRefPubMedGoogle Scholar
  66. Rodriguez, G.C., D. K. Walmer, et al. (1998). "Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis?" J Soc Gynecol Investig 5(5): 271–276.CrossRefPubMedGoogle Scholar
  67. Rodriguez-Burford, C, M.N. Barnes, et al. (2002). "Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as che-mopreventive agents." Clin Cancer Res 8(1): 202–209.PubMedGoogle Scholar
  68. Rosenblatt, K.A. and D.B. Thomas (1996). "Reduced risk of ovarian cancer in women with a tubal ligation or hysterectomy. The World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives." Cancer Epidemiol Biomarkers Prev 5(11): 933–935.PubMedGoogle Scholar
  69. Rosenthal, A. and I. Jacobs (1998). "Ovarian cancer screening." Semin Oncol 25(3): 315–325.PubMedGoogle Scholar
  70. Schildkraut, J.M. and W.D. Thompson (1988). "Familial ovarian cancer: a population-based case-control study." Am J Epidemiol 128(3): 456–466.PubMedGoogle Scholar
  71. Sellers, T.A., S. M. Gapstur, et al. (1993). "Association of body fat distribution and family histories of breast and ovarian cancer with risk of postmenopausal breast cancer." Am J Epidemiol 138(10): 799–803.PubMedGoogle Scholar
  72. Siskind, V., A. Green, et al. (2000). "Beyond ovulation: oral contraceptives and epithelial ovarian cancer." Epidemiology 11(2): 106–110.CrossRefPubMedGoogle Scholar
  73. Sit, A.S., F. Modugno, et al. (2002). "Hormone replacement therapy formulations and risk of epithelial ovarian carcinoma." Gynecol Oncol 86(2): 118–123.CrossRefPubMedGoogle Scholar
  74. Stanford, J.L. (1991). "Oral contraceptives and neoplasia of the ovary." Contraception 43(6): 543–556.CrossRefPubMedGoogle Scholar
  75. Steinberg, K.K., J.M. Pernarelli, et al. (1998). "Increased risk for familial ovarian cancer among Jewish women: a population-based case-control study." Genet Epidemiol 15(1): 51–59.CrossRefPubMedGoogle Scholar
  76. Supino, R., M. Crosti, et al. (1996). "Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression." Int J Cancer 65(4): 491–497.CrossRefPubMedGoogle Scholar
  77. Tavani, A., S. Gallus, et al. (2000). "Aspirin and ovarian cancer: an Italian case-control study." Ann Oncol 11(9): 1171–1173.CrossRefPubMedGoogle Scholar
  78. Thompson, H.J., C. Jiang, et al. (1997). "Sulfone metabolite of sulindac inhibits mammary carcinogenesis." Cancer Res 57(2): 267–271.PubMedGoogle Scholar
  79. Thompson, H.J., A. Wilson, et al. (1994). "Comparison of the effects of an organic and an inorganic form of selenium on a mammary carcinoma cell line." Carcinogenesis 15(2): 183–186.PubMedGoogle Scholar
  80. Tobacman, J.K., M. H. Greene, et al. (1982). "Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families." Lancet 2(8302): 795–797.CrossRefPubMedGoogle Scholar
  81. Toma, S., L. Isnardi, et al. (1997). "Effects of all-trans-retinoic acid and 13-cis-retinoic acid on breast-cancer cell lines: growth inhibition and apoptosis induction." Int J Cancer 70(5): 619–627.CrossRefPubMedGoogle Scholar
  82. Vachon, C.M., P.J. Mink, et al. (2002). "Association of parity and ovarian cancer risk by family history of breast or ovarian cancer in a population-based study of postmenopausal women." Epidemiology 13(1): 66–71.CrossRefPubMedGoogle Scholar
  83. van der Burg, M.E., F.B. Lammes, et al. (1993). "The role of CA 125 and conventional examinations in diagnosing progressive carcinoma of the ovary." Surg Gynecol Obstet 176(4): 310–314.PubMedGoogle Scholar
  84. van Nagell, J.R., Jr., P.D. DePriest, et al. (2000). "The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer." Gynecol Oncol 77(3): 350–356.CrossRefPubMedGoogle Scholar
  85. Walker, G.R., J.J. Schlesselman, et al. (2002). "Family history of cancer, oral contraceptive use, and ovarian cancer risk." Am J Obstet Gynecol 186(1): 8–14.CrossRefPubMedGoogle Scholar
  86. Whittemore, A.S., R. Harris, et al. (1992). "Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group." Am J Epidemiol 136(10): 1212–1220.PubMedGoogle Scholar
  87. Wu, M.L., A.S. Whittemore, et al. (1988). "Personal and environmental characteristics related to epithelial ovarian cancer. I. Reproductive and menstrual events and oral contraceptive use." Am J Epidemiol 128(6): 1216–1227.PubMedGoogle Scholar
  88. Yancik, R. (1993). "Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality." Cancer 71(2 Suppl): 517–523.PubMedGoogle Scholar
  89. Yawn, B. P., B.A. Barrette, et al. (2004). "Ovarian cancer: the neglected diagnosis." Mayo Clin Proc 79(10): 1277–1282.PubMedGoogle Scholar
  90. Zhang, M., C.W. Binns, et al. (2002). "Tea consumption and ovarian cancer risk: a case-control study in China." Cancer Epidemiol Biomarkers Prev 11(8): 713–718.PubMedGoogle Scholar
  91. Zhang, M., Z.Y. Yang, et al. (2002). "Diet and ovarian cancer risk: a case-control study in China." Br J Cancer 86(5): 712–717.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Berlin Heidelberg 2005

Authors and Affiliations

  • Kathryn Coe
    • 1
  • Ana Maria Lopez
    • 1
  • Lisa M. Hess
    • 1
  1. 1.College of MedicineUniversity of ArizonaTucson

Personalised recommendations